接受支架植入及后续双联抗血小板治疗患者出血并发症预测(PRECISE-DAPT)评分的推导与验证:临床试验个体患者数据集的汇总分析
该研究从8项多中心随机临床试验中汇总了14 963例冠状动脉支架术后接受DAPT(主要为阿司匹林加氯吡格雷、无口服抗凝指征)的患者个体数据,用Cox比例风险回归筛选院外TIMI大或小出血的预测因子,构建了包含年龄、肌酐清除率、血红蛋白、白细胞计数和既往自发性出血5项指标的PRECISE-DAPT评分。推导队列c-index为0.73(95%CI 0.61-0.85),PLATO试验验证队列(n=8595)为0.70(0.65-0.74),BernPCI注册验证队列(n=6172)为0.66(0.61-0.71)。在10 081例随机接受不同DAPT时长的患者中,评分≥25的高危患者延长DAPT(12-24个月)较短期(3-6个月)显著增加出血,而较低风险患者未见此增加(交互作用P=0.007),且缺血获益仅见于较低风险组。作者认为该评分可在综合临床评估背景下支持DAPT时长的决策。
要点
- PRECISE-DAPT评分由年龄、肌酐清除率、血红蛋白、白细胞计数、既往自发性出血5项组成,用于预测支架术后DAPT期间院外TIMI大或小出血。
- 推导队列c-index 0.73(95%CI 0.61-0.85),PLATO验证队列0.70(0.65-0.74),BernPCI注册验证队列0.66(0.61-0.71)。
- 评分≥25的高危患者延长DAPT(12-24个月)较短DAPT(3-6个月)显著增加出血,较低风险患者未见显著增加(交互作用P=0.007)。
- 缺血获益仅见于较低风险患者,高危患者延长DAPT未显示缺血获益。
- 作者认为该评分可在综合临床评估过程中支持DAPT时长的临床决策。
适用人群与场景
- 冠状动脉支架术后接受DAPT的患者,主要为阿司匹林加氯吡格雷,且无口服抗凝治疗指征。
- 推导队列来自8项多中心随机临床试验共14 963例患者;验证队列为PLATO试验中接受经皮冠状动脉介入治疗的患者(n=8595)和BernPCI注册患者(n=6172)。
- DAPT时长分析纳入随机分配至不同DAPT时长的患者共10 081例。
诊断标准与关键阈值
- PRECISE-DAPT评分包含5项:年龄、肌酐清除率、血红蛋白、白细胞计数、既往自发性出血。
- 评分≥25定义为高危患者。
- 结局为院外TIMI大或小出血。
处置流程与药物剂量
- 在综合临床评估过程中,使用PRECISE-DAPT评分辅助DAPT时长决策(作者认为该工具可支持临床决策)。
- 高危患者(评分≥25)延长DAPT(12-24个月)较短DAPT(3-6个月)显著增加出血。
- 较低风险患者延长DAPT未显著增加出血,且缺血获益仅见于该组。
研究设计与关键结果
- 研究类型为8项多中心随机临床试验个体患者数据的汇总分析,共14 963例支架术后接受DAPT的患者。
- 推导队列中PRECISE-DAPT评分预测院外TIMI大或小出血的c-index为0.73(95%CI 0.61-0.85)。
- PLATO试验验证队列(n=8595)c-index为0.70(95%CI 0.65-0.74),BernPCI注册验证队列(n=6172)c-index为0.66(95%CI 0.61-0.71)。
- 在10 081例随机分配至不同DAPT时长的患者中,评分≥25的高危患者延长DAPT(12-24个月)较短DAPT(3-6个月)显著增加出血,较低风险患者未见显著增加(交互作用P=0.007)。
- 缺血获益仅见于较低风险患者,高危患者延长DAPT未显示缺血获益。
证据类型、等级与局限
- 证据类型:基于8项多中心随机临床试验个体患者数据的汇总分析(推导与验证研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于支架术后接受DAPT且无口服抗凝指征的患者,可用PRECISE-DAPT评分评估院外出血风险,辅助DAPT时长决策(作者认为该工具可在综合临床评估过程中支持临床决策)。
- 评分≥25的高危患者延长DAPT(12-24个月)较短DAPT(3-6个月)显著增加出血,临床决策时需权衡。
- 较低风险患者延长DAPT未显著增加出血,且缺血获益仅见于该组。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor prevents ischaemic events after coronary stenting, but increases bleeding. Guidelines support weighting bleeding risk before the selection of treatment duration, but no standardised tool exists for this purpose.
METHODS: A total of 14 963 patients treated with DAPT after coronary stenting-largely consisting of aspirin and clopidogrel and without indication to oral anticoagulation-were pooled at a single-patient level from eight multicentre randomised clinical trials with independent adjudication of events. Using Cox proportional hazards regression, we identified predictors of out-of-hospital Thrombosis in Myocardial Infarction (TIMI) major or minor bleeding stratified by trial, and developed a numerical bleeding risk score. The predictive performance of the novel score was assessed in the derivation cohort and validated in patients treated with percutaneous coronary intervention from the PLATelet inhibition and patient Outcomes (PLATO) trial (n=8595) and BernPCI registry (n=6172). The novel score was assessed within patients randomised to different DAPT durations (n=10 081) to identify the effect on bleeding and ischaemia of a long (12-24 months) or short (3-6 months) treatment in relation to baseline bleeding risk.
FINDINGS: The PRECISE-DAPT score (age, creatinine clearance, haemoglobin, white-blood-cell count, and previous spontaneous bleeding) showed a c-index for out-of-hospital TIMI major or minor bleeding of 0·73 (95% CI 0·61-0·85) in the derivation cohort, and 0·70 (0·65-0·74) in the PLATO trial validation cohort and 0·66 (0·61-0·71) in the BernPCI registry validation cohort. A longer DAPT duration significantly increased bleeding in patients at high risk (score ≥25), but not in those with lower risk profiles (pinteraction=0·007), and exerted a significant ischaemic benefit only in this latter group.
INTERPRETATION: The PRECISE-DAPT score is a simple five-item risk score, which provides a standardised tool for the prediction of out-of-hospital bleeding during DAPT. In the context of a comprehensive clinical evaluation process, this tool can support clinical decision making for treatment duration.
参考来源
- Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017. PMID: 28290994. doi:10.1016/S0140-6736(17)30397-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。